MTRI

Mentari Therapeutics, Inc.

$12.20

-23.75%

SectorHealthcareIndustryBiotechnologyCountryUnited States

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.

Source: Yahoo Finance

Market Cap—

Dividend Yield—

Beta0.91

AI summary

Price & performance

1M-10.3%

3M-13.5%

YTD+8.9%

1Y-24.7%

52-week range—

Beta0.91

Full chart and returns against a benchmark

Q-Score

—/ 100

Quality against peers; 50 is the peer median.

No data available for Q-Scores.

Growth—

Risk—

Performance—

Valuation—

Profitability—

Leverage—

Sentiment—

Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue—

Net income-$12.6M

Net margin—

Historical fundamentals

Red flags in filings

3active red flags

Going-concern doubtSep 9, 2026

Auditor changeJun 13, 2025

Exchange listing noticeSep 18, 2026

Filings, findings and the timeline

Revenue exposure

Largest customer26%

Regions, segments, customers and suppliers

Valuation

MTRIIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B—6.22PEG—4.02

Dividend yield—

Every valuation metric

Earnings

Feb 10next report

EPS estimate—

Beats (last 4 quarters)—

Average surprise—

EPS revisions (30d)—

Every quarter against its estimate

Historical Fundamentals

Revenue

Net Income

Net Margin

Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2026	vs a year before	Q3 2026	vs a year before
Net Income	-$12.6M	—	-$2.3M	—

Obligations & Notes

From the notes to the annual report for fiscal 2026, ending June.

Impairments$189.2K

Earnings

The next report, and the record against analysts' estimates.

Next EPS estimate—

Beats (last 4 quarters)—

Average surprise—

EPS revisions (30d)—

No data available for Q-Scores.

Key Metrics

Fundamentals: trailing twelve months to Sep 2026, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.72SM 0.780.96

Volume

IM 693.1KSM 741.7K8.4K

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.

Company	Market cap	P/E	EV/EBITDA	P/S	P/B	FCF yield	Implied growth	Revenue growth	Op. margin	ROE	Debt/equity
MTRIMentari Therapeutics, Inc.	—	—	—	—	—	—	—	—	—	—	—
VRTXVertex Pharmaceuticals Incorporated	$138.9B	34.9	30.5	10.7	6.6	2.3%	15.9%	10.5%	33.2%	19.0%	0.2
MRNAModerna, Inc.	$101.5B	—	—	40.2	14.8	-1.9%	—	13.1%	-116.0%	-40.8%	0.1
REGNRegeneron Pharmaceuticals, Inc.	$94.8B	19.7	17.3	5.6	2.8	4.0%	8.2%	18.6%	28.8%	14.4%	0.1
ARGXargenx SE	$61.1B	47.3	54.7	14.7	8.3	1.1%	25.0%	89.9%	25.4%	17.6%	0.0
ONCBeOne Medicines AG	$48.4B	52.9	32.2	7.3	8.3	3.0%	11.1%	32.9%	17.8%	15.7%	0.2
RVMDRevolution Medicines, Inc.	$41.8B	—	—	—	17.4	-3.5%	—	—	-853.0%	-77.9%	0.0
RPRXRoyalty Pharma plc	$39.9B	59.4	32.0	15.3	4.1	7.4%	2.9%	11.4%	57.1%	6.9%	0.9
GMABGenmab A/S	$33.3B	34.5	34.3	8.9	5.7	3.5%	11.8%	19.2%	28.6%	16.5%	0.9
Industry median		11.7	20.2	7.7	2.2	-22.3%	9.9%	12.8%	-76.9%	-60.8%	0.0
MTRI percentile		—	—	—	—	—	—	—	—	—	—